Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation

@article{Xie2020CombinationEO,
  title={Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation},
  author={C. Xie and Jindong Kong and Fujun Miao and Xuan-jun Wang and Jun Sheng},
  journal={Thoracic Cancer},
  year={2020},
  volume={11},
  pages={2101 - 2111}
}
  • C. Xie, Jindong Kong, +2 authors Jun Sheng
  • Published 2020
  • Medicine
  • Thoracic Cancer
  • Abstract Background Epidermal growth factor receptor H773_V774 insH (EGFR‐insH) is an EGFR exon 20 insertion mutation in non‐small cell lung cancer (NSCLC), which is naturally resistant to available EGFR tyrosine kinase inhibitors (TKIs) and lacks a patient‐derived cell line. Methods A Ba/F3 cell line expressing EGFR‐insH mutation (Ba/F3‐insH cell line) was generated using an IL3‐deprivation method. A cell proliferation assay was performed to screen natural compounds that exhibit a synergistic… CONTINUE READING

    References

    SHOWING 1-10 OF 48 REFERENCES
    Apoptotic markers in a prostate cancer cell line: effect of ellagic acid.
    • 36
    • PDF
    Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth
    • 37
    • PDF
    Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
    • 20